1. Takaki, H., S. Kure, H. Oshiumi, H. Y. Sakoda, T. Suzuki, A. Ainai, H. Hasegawa, M. Matsumoto, and T. Seya. 2018. Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production. Mucosal Immunol. 11: 82-96.
  2. Yoshida S, H. Shime, Y. Takeda, N. Jim-min, K. Takashima, M. Matsumoto, H. Shirato, M. Kasahara, T. Seya. 2018. Radiation-induced tumor regression is augmented by pre-TLR3 stimulation with polyIC in mouse models. Cancer Sci.109: 956-965.
  3. Nakamura H, Oku K, Ogata Y, Ohmura K, Yoshida Y, Kitano E, Fujieda Y, Kato M, Bohgaki T, Amengual O, Yasuda S, Fujimura Y, Seya T, Atsumi T. 2018. Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome.Thromb Res.164: 63-68
  4. Takeda, Y., M. Azuma, K. Funami, H. Shime, M. Matsumoto, and T. Seya. 2018. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.Front Immunol.9: 496.
  5. Takashima, K., H. Oshiumi, M. Matsumoto, and T. Seya. 2018. TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cells. Biochem Biophys Res Commun.499: 985-991.
  6. Takeda, Y., S. Yoshida, K. Takashima, N. Ishii-Mugikura, H. Shime, T. Seya, and M. Matsumoto. 2018. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.Cancer Sci.109: 2119-2129.
  7. Takeda, Y., M. Azuma, R. Hatsugai, Y Fujimoto, M. Hashimoto, K. Fukase, M. Matsumoto, and T. Seya. 2018. The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells.Innate Immun.24: 323-331.
  8. Takeda, Y., H. Takaki, A. Miyazaki, S. Yoshida, M. Matsumoto, and T. Seya. 2018. Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.Biochem Biophys Res Commun.506: 1019-1025.
  9. Seya, T., Y. Takeda, K. Takashima, S. Yoshida, M. Azuma, and M. Matsumoto. 2018. Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.Proc Jpn Acad, Series B. 94: 153-160.
  10. Takaki, H., S. Ichimiya, M. Matsumoto, and T. Seya. 2018. Mucosal immune response in nasal-associated lymphoid tissue upon intranasal administration by adjuvants.J Innate Immun. 10: 515-521.
  11. Tatematsu, M., K. Funami, T. Seya, and M. Matsumoto. 2018. Extracellular RNA Sensing by Pattern Recognition Receptors.J Innate Immun.10: 398-406.